Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities

Antzeko izenburuak

• Bcr-Abl tyrosine kinase inhibitors- current status
  nork: Mughal, Anum, et al.
  Argitaratua: (2013)
• The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
  nork: Hantschel, Oliver, et al.
  Argitaratua: (2007)
• Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
  nork: Byrgazov, Konstantin, et al.
  Argitaratua: (2016)
• Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
  nork: Carofiglio, Francesca, et al.
  Argitaratua: (2020)
• A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
  nork: Tong, Bingqi, et al.
  Argitaratua: (2020)